Clinical research progress of non-small cell lung cancer harboring EGFR gene exon 20 insertion mutation

VernacularTitle:EGFR基因20号外显子插入突变型非小细胞肺癌的临床研究进展
Author: Ping QI ¹ ; Xiaoming HOU ; Jinghua LI ; Dan DU ; Longxia ZHANG ; Hui QIAO
Author Information

1. 兰州大学第一临床医学院,甘肃兰州 730000
Publication Type:Journal Article
Keywords: Non-small cell lung cancer; Epidermal growth factor receptor; Exon 20 insertion mutation
From: Tumor 2025;45(2):191-201
CountryChina
Language:Chinese
Abstract: Epidermal growth factor receptor(EGFR)gene exon 20 insertion(ex20ins)mutation is a common driver gene activation mutation in non-small cell lung cancer(NSCLC).Tumors harboring this gene mutation are characterized by high heterogeneity,high malignancy,low detectability,poor response to conventional therapies,and poor prognosis.In recent years,significant progress has been made in the study of EGFR ex20ins mutation.The wide application of next-generation sequencing has improved the detection rate.The U.S.Food and Drug Administration(FDA)has approved the relevant indications of amivantamab in NSCLC patients with EGFR ex20ins mutation.A variety of new drugs have also achieved good results in previous studies.This article will summarize the structural characteristics,detection methods and clinical treatment progress of NSCLC patients with EGFR ex20ins mutations,hoping to provide help for the choice of clinical treatment for such patients.